Overview

Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD

Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
A Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to investigate Efficacy and Safety of Sevuparin Infusion for the Management of Acute Vaso-Occlusive Crisis (VOC) in Subjects with Sickle-Cell Disease (SCD).
Phase:
Phase 2
Details
Lead Sponsor:
Dilaforette AB
Modus Therapeutics AB
Collaborator:
Ergomed